N/A N=32 Effectiveness of Astym Treatment For de Quervain's Tenosynovitis
de Quervain's Disease
Primary: Numeric Rating Scale for Pain — 3.2; 2.1 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Proximal Urethral Cancer
Primary: Objective Response Rate — 56.4 percentage of participants
Phase 2 N=263 A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Choroidal Neovascularization
Primary: Mean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants — 7.61; 9.18; 6.02; 6.10 BCVA Letters — p=0.5244
N/A N=32 Microcurrent Dressing to Treat Infections, Before, During and After Surgery
Shoulder Arthropathy Associated With Other Conditions · Shoulder Arthritis · Shoulder Osteoarthritis
Primary: Measurement of Change in Cutibacterium Acnes — 3; 8; 3; 2 Participants — p=0.004
Phase 3 N=400 Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
Covid19
Primary: Number of Patients With Early Clinical Improvement — 111; 80 Participants — p=<0.03
N/A N=27 ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
Parkinson's Disease
Primary: Number of Adverse Events — 100; 10 Number of Adverse Events
Phase 4 N=18 Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.
Obesity
Primary: Fasting Glucose — 4.8; 5.0 mmol/L — p=0.327
Phase 3 N=157 MLD10 in the Prevention of Migraine in Adults
Migraine
Primary: Migraine Headache Days — 7.12; 6.92; 5.53; 4.79 Days
Phase 4 N=201 Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
Chronic Heart Failure With Reduced Ejection Fraction
Primary: Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 3 Months of Treatment — 0.51; 0.19 mL/kg/min — p=0.2327
Phase 3 N=578 A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 5.2; 7.7 Months — p=<0.0001
N/A N=104 Interventional Study to Decrease Cardiovascular Risk in Women in Primary Health Care in South Croatia
Cardiovascular Risk Factor
Primary: Ten Year Risk of Cardiovascular Disease (CVD) — 2.9 percentage of risk
N/A N=20 Perioral Rejuvenation and Upper Lip Enhancement
Perioral Rejuvenation · Upper Lip Projection
Primary: Nasal Tip Projection — 0.601 ratio
Phase 2 N=216 Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection
Hepatitis C Virus Infection
Primary: PK Lead-in Phase: AUCtau: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval of Velpatasvir (VEL) — 4479.3; 3697.5; 4450.3 hours*nanograms…
N/A N=75 Assessing Mechanisms of Anxiety Reduction in Animal-assisted Interventions
Social Anxiety Disorder · Social Anxiety · Social Anxiety Disorder of Childhood
Primary: Self-reported Affective Experience — 10.19; 10.00; 10.28; 8.33 units on a scale — p=.723
Phase 2 N=162 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Hypertension, Portal
Primary: Change in Portal Pressure at Year 1 (Change in HVPG From Baseline and 1 Year) — -0.39; -0.24; 0.19 mm HG — p=1.000